News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
01
2025
-
12
Our core products have once again been honored! Two products from Linuo Pharmaceutical have made the list of “Family Essential Medicines” brands!
Classification：
行业新闻
Corporate News
11 On the 18th, the award ceremony for the “2024-2025 List of Recommended Household Medicines,” hosted by Family Doctor Online, came to a successful conclusion during the autumn Nanjing session of the 91st National Pharmaceutical Fair. As an authoritative benchmark in the field of family health medications, this event is hailed within the industry as the “weathervane for household health essentials.” All brands featured on the list have undergone multiple rigorous rounds of screening—including qualification reviews, market research, public voting, and expert evaluations—ensuring both the quality and reputation of the selected products while also providing consumers with a scientifically sound guide to preparing their home medicine cabinets. At the same time, the event has established a platform for pharmaceutical companies to focus on people’s health needs and promote high-quality development, effectively serving as a vital bridge between the strength of the pharmaceutical industry and the demands of family health.
In this selection, Linuo Pharmaceutical has earned three prestigious awards thanks to its deep industry experience, outstanding product quality, and widespread market recognition: The company has been honored with the “Consumer-Favorite Enterprise Award,” highlighting its comprehensive brand strength and strong market reputation; its core product, Fures ® Aminecaine Ointment, has been named a featured brand in the “Oral and Throat Medicines” category, while Xinsu ® Isosorbide Dinitrate Spray has been selected as a featured brand in the “Cardiovascular and Cerebrovascular Medicines” category! These honors not only reflect the high level of recognition from both the industry and consumers but also serve as powerful testament to the company’s unwavering commitment to deepening its presence in the pharmaceutical sector and staying true to its original dedication to quality.
Linuo Pharmaceutical Wins the “Consumer-Favorite Enterprise Award”
Foris® Aminecaine Paste Named as a Featured Brand in the “Oral and Throat Medication” Category
Xinshu® Isosorbide Dinitrate Spray Selected as a Featured Brand in the “Cardiovascular and Cerebrovascular Drugs” Category
Strength builds glory; craftsmanship safeguards health.
Founded in 2002, Linuo Pharmaceutical is a wholly-owned subsidiary of the publicly listed company Keyuan Pharmaceutical (stock code: 301281.SZ). It is one of China’s fastest-growing pharmaceutical companies and a specialized, sophisticated, and innovative enterprise in Jinan City.
In recent years, the company has accelerated its digital and intelligent transformation, establishing three major smart manufacturing bases in Shanghe, Yinan, and Jinan. Leveraging AI-powered capabilities, capital-driven leadership, and integrated advantages across raw materials, excipients, and finished dosage forms, the company has built a diversified product portfolio encompassing injectables, oral solutions, drops, lotions, pastes, and sprays. As a result, the company has developed competitive advantages in cost control, quality, and production capacity.
The attainment of these three honors is both a high recognition from the industry and the market of Linuo Pharmaceutical’s over 20-year commitment to the corporate spirit of “caring for life and health, and safeguarding a better life,” as well as a comprehensive affirmation of the company’s R&D strength, production quality control, and market services. Moving forward, Linuo Pharmaceutical will continue to drive product upgrades and innovative R&D, delivering even higher-quality pharmaceutical products and services to implement the “Healthy China” strategy. We will live up to consumers’ trust and the industry’s expectations, and forge ahead with determination on the path to safeguarding the health of all people!
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
2026-05-13
On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediate, Packaging & Equipment Exhibition (API China) opened in grand style at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing a coordinated approach to APIs and finished dosage forms, a comprehensive end-to-end product portfolio, and strong brand synergy. The company highlighted its robust capabilities in innovative R&D, digital and intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore emerging industry trends, expand new avenues of collaboration, and co‑create a thriving new ecosystem for the pharmaceutical and healthcare sectors.
2026-05-07
On May 6, Lino Pharmaceutical, a subsidiary of Keyuan Pharmaceutical (stock code: 301281.SZ), held a company-wide meeting in Jinan. Centered on the core principle of “unified strategy across the entire workforce and coordinated action across all business units,” the meeting comprehensively communicated the company’s development strategy and outlined the implementation roadmap, aligning the thinking and building consensus among all employees. With a spirit of concerted effort and synchronized momentum, the meeting charted a new blueprint for the company’s high-quality development.
2026-05-07
Recently, the Jinan Municipal Federation of Trade Unions officially announced the list of winners for the 2025 “Making Contributions in the Spring City” Innovation and Excellence Labor Competition. Shandong Linuo Pharmaceutical Co., Ltd.’s Solid Dosage Form Workshop stood out among numerous outstanding work teams across the city thanks to its remarkable performance, rigorous work style, and exceptional innovative capabilities, earning the prestigious First Prize for Work Teams.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China